Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study

References

• Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A. The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):104–109. doi:10.2174/1570161117666190405165911
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation; 2021. Available from: https://www.diabetesatlas.org. Accessed March 25, 2024.
   Google Scholar
• Pearson ER. Type 2 diabetes: a multifaceted disease. Diabetologia. 2019;62(7):1107–1112. doi:10.1007/s00125-019-4909-y
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi:10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Damaskos C, Garmpis N, Kollia P, et al. Assessing cardiovascular risk in patients with diabetes: an update. Curr Cardiol Rev. 2020;16(4):266–274. doi:10.2174/1573403X15666191111123622
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al.; on behalf of the American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–S157. doi:10.2337/dc23-S009
   PubMedGoogle Scholar
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001
   PubMed Web of Science ®Google Scholar
• Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019;20(6):805–815. doi:10.1111/obr.12839
   PubMed Web of Science ®Google Scholar
• Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:645563. doi:10.3389/fendo.2021.645563
   PubMed Web of Science ®Google Scholar
• Yoshiji S, Minamino H, Tanaka D, Yamane S, Harada N, Inagaki N. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: a meta-analysis and meta-regression analysis. Diabetes Obes Metab. 2022;24(6):1029–1037. doi:10.1111/dom.14666
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1–7 trials. Diabetes Metab. 2019;45(5):409–418. doi:10.1016/j.diabet.2018.12.001
   PubMed Web of Science ®Google Scholar
• Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442–451. doi:10.1111/dom.13955
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al.; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. doi:10.1016/S2213-8587(18)30024-X
   PubMed Web of Science ®Google Scholar
• Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563–574. doi:10.1016/S2213-8587(21)00174-1
   PubMed Web of Science ®Google Scholar
• Marzullo P, Daffara T, Mele C, et al. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. J Endocrinol Invest. 2022;45(8):1587–1598. doi:10.1007/s40618-022-01799-2
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al.; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
   PubMed Web of Science ®Google Scholar
• Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610–619. doi:10.1111/dom.13120
   PubMed Web of Science ®Google Scholar
• Verma S, McGuire DK, Bain SC, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487–2492. doi:10.1111/dom.14160
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785. doi:10.1016/S2213-8587(19)30249-9
   PubMed Web of Science ®Google Scholar
• Peter R, Bain SC. Safety of injectable semaglutide for type 2 diabetes. Expert Opin Drug Saf. 2020;19(7):785–798. doi:10.1080/14740338.2020.1772230
   PubMed Web of Science ®Google Scholar
• Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(9):2255–2263. doi:10.1111/dom.13361
   PubMed Web of Science ®Google Scholar